Detailed Information on Publication Record
2007
Radiographic progression of rheumatoid arthritis in patients from the Czech National Registry receiving infiiximab treatment
PAVELKA, K., J. GATTEROVA, D. TEGZOVA, K. JAROSOVA, J.T. STUDYNKOVA et. al.Basic information
Original name
Radiographic progression of rheumatoid arthritis in patients from the Czech National Registry receiving infiiximab treatment
Name in Czech
Radiographic progression of rheumatoid arthritis in patients from the Czech National Registry receiving infiiximab treatment
Authors
PAVELKA, K. (203 Czech Republic), J. GATTEROVA (203 Czech Republic), D. TEGZOVA (203 Czech Republic), K. JAROSOVA (203 Czech Republic), J.T. STUDYNKOVA (203 Czech Republic), Adam SVOBODNÍK (203 Czech Republic), J. SVIHALEK (203 Czech Republic), Ladislav DUŠEK (203 Czech Republic, guarantor) and J. VENCOVSKY (203 Czech Republic)
Edition
Clinical and Experimental Rheumatology, 2007, 0392-856X
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30000 3. Medical and Health Sciences
Country of publisher
Italy
Confidentiality degree
není předmětem státního či obchodního tajemství
Impact factor
Impact factor: 2.270
RIV identification code
RIV/00216224:14110/07:00033158
Organization unit
Faculty of Medicine
UT WoS
000249556400006
Keywords in English
rheumatoid arthritis; biological treatment; radiographic progression
Změněno: 1/4/2010 08:42, prof. RNDr. Ladislav Dušek, Ph.D.
V originále
Objective To evaluate the clinical status and radiographic progression in patients with rheamzatoid arthritis (RA) being followed by the Czech National Registry of biological treatments. Methods Patients who failed at least two disease-modifying antirheumatic drugs and had high disease activity (DAS28 > 5.1) were treated with infliximab. Radiographic progression was measured with a modified version of the Sharp score (TSS) after 54 weeks of treatment. Results Ninety-nine patients with an average disease duration of 13.7 years were enrolled. The DAS28 dropped from 6.66 to 4.07 (p < 0.001). Before treatment the mean TSS was 90.1 and the mean estimated yearly disease progression was 8.56. After 54 weeks of infliximab, radiographic progression was 4.15 times slower than the estimated rate before treatment and 63 patients did not show any radiographic progression at all. In the remaining 36 patients, the progression rate slowed to 3.8 +/- 0.9 from the estimated TSS of 10.9 +/- 6.9 before the initiation of treatment (p = 0.011). Conclusion Data derived from the Czech National Registry, which reflect general clinical practice, show a significant retardation of radiographic progression in patients treated with anti-TNF and the magnitude of the improvement seen is similar to results from clinical trials
In Czech
Objective To evaluate the clinical status and radiographic progression in patients with rheamzatoid arthritis (RA) being followed by the Czech National Registry of biological treatments. Methods Patients who failed at least two disease-modifying antirheumatic drugs and had high disease activity (DAS28 > 5.1) were treated with infliximab. Radiographic progression was measured with a modified version of the Sharp score (TSS) after 54 weeks of treatment. Results Ninety-nine patients with an average disease duration of 13.7 years were enrolled. The DAS28 dropped from 6.66 to 4.07 (p < 0.001). Before treatment the mean TSS was 90.1 and the mean estimated yearly disease progression was 8.56. After 54 weeks of infliximab, radiographic progression was 4.15 times slower than the estimated rate before treatment and 63 patients did not show any radiographic progression at all. In the remaining 36 patients, the progression rate slowed to 3.8 +/- 0.9 from the estimated TSS of 10.9 +/- 6.9 before the initiation of treatment (p = 0.011). Conclusion Data derived from the Czech National Registry, which reflect general clinical practice, show a significant retardation of radiographic progression in patients treated with anti-TNF and the magnitude of the improvement seen is similar to results from clinical trials
Links
| 1M0571, research and development project |
|